See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Baseball
Natural Disasters
Social Media
Tariffs
Tennis
Soccer
Golf
Donald Trump
Floods
Boxing
Hockey
NBA
Published • loading... • Updated

Ceva Animal Health Expands Investment to Advance Innovation in Vaccines, Gene Therapy

Summary by petage.com
Ceva Animal Health, the world’s fifth-largest animal health company, has announced the restructuring of its capital. All investors, whether “Friends of Ceva” or pure investors led by Temasek, have renewed their investment, demonstrating their confidence in the company’s ability to continue its sustained growth. Ceva’s management, led by Dr. Marc Prikazsky, has reinforced its participation and still retains the majority of voting rights, reaffirm…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
petage.competage.com

Ceva Animal Health Expands Investment to Advance Innovation in Vaccines, Gene Therapy

Ceva Animal Health, the world’s fifth-largest animal health company, has announced the restructuring of its capital. All investors, whether “Friends of Ceva” or pure investors led by Temasek, have renewed their investment, demonstrating their confidence in the company’s ability to continue its sustained growth. Ceva’s management, led by Dr. Marc Prikazsky, has reinforced its participation and still retains the majority of voting rights, reaffirm…

Read Full Article
Hemophilia News TodayHemophilia News Today

Hemophilia B gene therapy Hemgenix now reimbursed in Germany

The cost of the one-time hemophilia B gene therapy Hemgenix (etranacogene dezaparvovec) will now be covered for eligible patients in Germany through the country’s public healthcare system. This comes through a reimbursement price agreement between developer CSL Behring and GKV-Spitzenverband, the German National Association of Statutory Health Insurance Funds. “The agreement on the reimbursement price of Hemgenix is a decisive step for the care …

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Hemophilia News Today broke the news in on Friday, April 4, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Vaccines

Vaccines

Germany

Germany

France

France

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal